Research Priorities for Precision Medicine in NAFLD

Paula Iruzubieta; Ramon Bataller; María Teresa Arias-Loste; Marco Arrese; José Luis Calleja; Graciela Castro-Narro; Kenneth Cusi; John F Dillon; María Luz Martínez-Chantar; Miguel Mateo; Antonio Pérez; Mary E Rinella; Manuel Romero-Gómez; Jörn M Schattenberg; Shira Zelber-Sagi; Javier Crespo; Jeffrey V Lazarus

doi:10.1016/j.cld.2023.01.016

Research Priorities for Precision Medicine in NAFLD

Clin Liver Dis. 2023 May;27(2):535-551. doi: 10.1016/j.cld.2023.01.016. Epub 2023 Feb 26.

Authors

Paula Iruzubieta¹, Ramon Bataller², María Teresa Arias-Loste¹, Marco Arrese³, José Luis Calleja⁴, Graciela Castro-Narro⁵, Kenneth Cusi⁶, John F Dillon⁷, María Luz Martínez-Chantar⁸, Miguel Mateo⁹, Antonio Pérez¹⁰, Mary E Rinella¹¹, Manuel Romero-Gómez¹², Jörn M Schattenberg¹³, Shira Zelber-Sagi¹⁴, Javier Crespo¹⁵, Jeffrey V Lazarus¹⁶

Affiliations

¹ Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Avenida Valdecilla 25, 39008, Santander, Spain.
² Division of Gastroenterology, Hepatology and Nutrition, Center for Liver Diseases, University of Pittsburgh Medical Center, PA, USA.
³ Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Avenida Libertador Bernardo O'Higgins 340, 8331150, Santiago, Chile.
⁴ Department of Gastroenterology and Hepatology, Puerta de Hierro University Hospital, Puerta de Hierro Health Research Institute (IDIPHIM), CIBERehd, Universidad Autonoma de Madrid, Calle Joaquín Rodrigo 1, 28222, Majadahonda, Spain.
⁵ Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Hepatology and Transplant, Hospital Médica Sur, Asociación Latinoamericana para el Estudio del Hígado (ALEH), Mexico City, Mexico.
⁶ Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Florida, Gainesville, FL, USA.
⁷ Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
⁸ Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Centro de Investigación Biomedica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Derio, Bizkaia, Spain.
⁹ Pharmacy Organisation and Inspection, Government of Cantabria, Santander, Spain.
¹⁰ Endocrinology and Nutrition Department, Santa Creu I Sant Pau Hospital, Universitat Autónoma de Barcelona, IIB-Sant Pau and Centro de Investigación Biomedica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
¹¹ Department of Medicine, University of Chicago, Chicago, IL, USA.
¹² UCM Digestive Diseases and CIBERehd, Virgen Del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain.
¹³ Metabolic Liver Research Program, I. Department of Medicine, University Medical Centre Mainz, Mainz, Germany.
¹⁴ University of Haifa, School of Public Health, Mount Carmel, Haifa, Israel; Department of Gastroenterology, Tel- Aviv Medical Centre, Tel- Aviv, Israel.
¹⁵ Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Avenida Valdecilla 25, 39008, Santander, Spain. Electronic address: javiercrespo1991@gmail.com.
¹⁶ Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Calle del Rossellón 171, ENT-2, Barcelona ES-08036, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA. Electronic address: jeffrey.lazarus@isglobal.org.

PMID: 37024222
DOI: 10.1016/j.cld.2023.01.016

Abstract

NAFLD is a multisystem condition and the leading cause of chronic liver disease globally. There are no approved NAFLD-specific dugs. To advance in the prevention and treatment of NAFLD, there is a clear need to better understand the pathophysiology and genetic and environmental risk factors, identify subphenotypes, and develop personalized and precision medicine. In this review, we discuss the main NAFLD research priorities, with a particular focus on socioeconomic factors, interindividual variations, limitations of current NAFLD clinical trials, multidisciplinary models of care, and novel approaches in the management of patients with NAFLD.

Keywords: Disease phenotyping; Multidisciplinary care; NAFLD; Non-invasvie tests (NITs); Precision medicine.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Non-alcoholic Fatty Liver Disease* / drug therapy
Non-alcoholic Fatty Liver Disease* / therapy
Precision Medicine